PBP1510 (Ulenistamab) Anti-PAUF Antibody for Pancreatic Cancer
Product Description
Prestige Biopharma Limited
-
SG -
2018On CPHI since
-
250 - 499Employees
Company types
Primary activities
.png)
Categories
Specifications
Prestige Biopharma Limited
-
SG
-
2018On CPHI since
-
250 - 499Employees
Company types
Primary activities
More Products from Prestige Biopharma Limited (2)
-
Product PBP1510 (INN:ULENISTAMAB)
Ulenistamab (PBP1510) is a First-in-Class antibody drug developed as a target of pancreatic adenocarcinoma up-regulated factor (PAUF) resulting in decreased autocrine and paracrine signaling implicated pancreatic cancer. It attenuates the tumorigenic potential of PAUF in both the pancreatic cancer cells an... -
Product PAUF Pancreatic Cancer Diagnostic Kit
Pancreatic Adenocarcinoma Up-regulated Factor- PAUF is over-expressed in over 80% of pancreatic adenocarcinoma (PDAC). With our expertise in biosimilars and novel antibody drugs development and manufacturing, we are strongly positioned to tackle the unaddressed need of pancreatic cancer. Early detection an...
Prestige Biopharma Limited resources (1)
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance